VEGF-A
11 drugs MetabolicOncology
5
approved indications
11
Approved Drugs
7
Companies
15
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (7 companies)
✓ All 11 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (15 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Roche 3 drugs
Novartis 2 drugs
Regeneron 2 drugs
By Therapeutic Area
Metabolic 7 drugs
Other 3 drugs
By Therapeutic Area
Metabolic 7 drugs
CIMERLI, EYDENZELT, PAVBLU, EYLEA HD +3 more
Other 3 drugs
LUCENTIS, EYLEA, BYOOVIZ
Oncology 1 drugs
ZALTRAP
Indications Treated
Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Diabetic Macular Edema (DME)Diabetic Retinopathy (DR)Myopic Choroidal Neovascularization (mCNV)Neovascular Age-Related Macular DegenerationMacular Edema Following Retinal Vein OcclusionDiabetic Macular EdemaDiabetic RetinopathyMyopic Choroidal NeovascularizationRetinopathy of Prematurity (ROP)Macular EdemaRetinal Vein OcclusionColorectal CancerNeovascular Age-related Macular Degeneration
All Drugs Targeting VEGF-A
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| LUCENTIS | Roche | 2006 | 5 | |
| CIMERLI | Novartis | 2022 | 5 | Metabolic |
| EYLEA | Regeneron | 2011 | 5 | |
| EYDENZELT | CELLTRION INC | 2025 | 5 | Metabolic |
| PAVBLU | Amgen | 2024 | 5 | Metabolic |
| BYOOVIZ | SAMSUNG BIOEPIS CO LTD | 2021 | 4 | |
| EYLEA HD | Regeneron | 2023 | 4 | Metabolic |
| VABYSMO | Roche | 2022 | 3 | Metabolic |
| SUSVIMO | Roche | 2021 | 3 | Metabolic |
| BEOVU | Novartis | 2019 | 2 | Metabolic |
| ZALTRAP | Sanofi | 2012 | 1 | Oncology |